SMi's Inaugural Pharmaceutical Manufacturing & Cleanroom Technology Conference

SMi Group 9 - 10 October 2019, London, UK.
SMi Group are pleased to announce the Inaugural Pharmaceutical Manufacturing & Cleanroom Technology Conference, taking place on the 9th and 10th October 2019 in London, UK. As the first event in Europe that focuses on cleanroom technology and aseptic manufacturing in the pharmaceutical industry, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point.

This one-of-a-kind meeting will facilitate networking opportunities with key opinion leaders from all areas of pharmaceuticals, biologicals, manufacturing and cleanroom industry experts to explore hot topics within cleanroom design and engineering, best practices and regulation, environmental and contamination control, aseptic processing, sterility assurance, quality risk management and pharmaceutical microbiology.

In 2025, the global cleanroom technology market is expected to reach nearly $5 billion. Stringent regulatory standards for product approvals, technological advancements in cleanrooms, initiatives taken by private organisations to create awareness regarding cleanroom and growth of the healthcare sector globally are among the few factors expected to drive the market.

Compliance with the standards for product approvals is crucial and as a result manufacturing companies in various industries are dependent on cleanroom and barrier technologies.

Benefits of attending

  • Explore the characteristics and relevance of air flow to better advise cleanroom design, engineering and manage contamination
  • Discuss the most current approaches to minimised cost and improved energy efficiency without compromising product quality
  • Examine the latest contamination control strategies from leaders in the pharmaceutical industry
  • Gain insight into cleaning and disinfection protocols from a risk-management approach

Plus an Interactive Half Day Pre-Conference Workshop

Tuesday 8th October 2019, Copthorne Tara Hotel, London, UK
Environmental Classification, Qualification and Monitoring of GMP Controlled areas referencing ISO 14644-1 and risk based GMP
Workshop Leader: James Drinkwater, Chairman, Pharmaceutical and Healthcare Science Society

For more information and to register, plase visit www.cleanroomtechnology.co.uk/wpnWB

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Amgen to acquire Otezla® for $13.4 billion in cash

Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with...